Liraglutide, what the science actually shows

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza (type 2 diabetes) and Saxenda (weight management). Evidence base: extensive human RCT data across the SCALE trial series for weight management and diabetes.

An FDA-approved GLP-1 receptor agonist that paved the way for the weight loss revolution. Marketed as Victoza for diabetes and Saxenda for obesity. Same mechanism as semaglutide, shorter duration.

Evidence
★★★★★ Robust
Type
GLP-1 Agonist
Structure
Acylated 31-amino-acid peptide

What liraglutide is

Synthetic analogue of human GLP-1 with 97% structural similarity. Developed by Novo Nordisk. Fatty acid chain extends half-life from 2 minutes to 13 hours. Approved as Victoza (1.8mg, diabetes, 2010) and Saxenda (3.0mg, weight management, 2014).

Mechanism, in plain English

Activates GLP-1 receptors in pancreas (increases insulin in response to food), brain (reduces appetite via satiety centers), and gut (slows gastric emptying). You feel full sooner, stay full longer, blood sugar is better controlled. Glucose-dependent mechanism reduces hypoglycemia risk.

Want all weight loss compounds in one place?

Get the Weight Loss & Metabolism Guide →

What the evidence shows

LEADER trial (9,340 patients, 3.8 years): reduced cardiovascular events by 13%. SCALE trial (3,731 patients): 8% body weight loss vs 2.6% placebo over 56 weeks. Head-to-head with semaglutide: semaglutide produces greater weight loss, but liraglutide has longer safety track record.

FDA status

FDA-approved. Victoza (2010) for type 2 diabetes. Saxenda (2014) for chronic weight management.

Common synonyms

Liraglutide, Victoza, Saxenda, NN2211

Safety and adverse-event landscape

Decade+ of data. Most common: nausea (40% initially, improves), diarrhea, constipation. Rare: pancreatitis, gallbladder events. Black box warning for medullary thyroid carcinoma (rodent finding, unconfirmed in humans).

Frequently asked questions

Both GLP-1 agonists. Semaglutide is newer, more potent, weekly vs daily. About 5% more weight loss on average. Liraglutide has longer safety record and lower cost in some markets.
Common. Current guidance treats obesity as chronic condition requiring ongoing management.
Yes. 31-amino-acid acylated peptide resembling natural GLP-1.
No. Peptexa is educational only.

Related on Peptexa

Semaglutide, next-gen GLP-1 Tirzepatide, dual GIP/GLP-1 All weight loss peptides Take the peptide quiz

The full Weight Loss & Metabolism reference

Mechanism, evidence level, and FDA status for every compound.

Get the Weight Loss & Metabolism Guide →